Jamie E. Chaft

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer

  JAMA · 2026-06-01

• Circulating tumor DNA dynamics following molecularly targeted therapy for non–small cell lung cancer.

  Journal of Clinical Oncology · 2026-05-28

• Adjuvant erlotinib versus observation after complete resection of <i>EGFR</i> -mutant NSCLC: Final overall survival results of Alliance A081105.

  Journal of Clinical Oncology · 2026-05-28

• Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST).

  Journal of Clinical Oncology · 2026-05-28

• Beamion LUNG-3: Zongertinib in resectable <i>HER2</i> -mutant NSCLC.

  Journal of Clinical Oncology · 2026-05-28

• Post-progression treatment strategies and immunotherapy rechallenge sensitivity following chemoradiation and consolidation durvalumab in unresectable stage III NSCLC: The POST-PACIFIC study.

  Journal of Clinical Oncology · 2026-05-28

• Fusion-positive early-stage and locally advanced lung cancers: A real-world analysis of event-free, disease-free, and overall survival.

  Journal of Clinical Oncology · 2026-05-28

• Differences in central versus local lab PD-L1 classification in the ALCHEMIST Alliance A151216 non–small cell lung cancer (NSCLC) study.

  Journal of Clinical Oncology · 2026-05-28

• Multimodal Impact of Number of Metastases and Genetic Alterations on Survival in Metastatic Non–Small Cell Lung Cancer

  JCO Precision Oncology · 2026-05-01

• Treatments for human epidermal growth factor receptor 2 (HER2)–altered cancers evaluated using a tumor‑agnostic approach: A narrative review

  Cancer Treatment Reviews · 2026-04-17

• Study Designs for INTerpath-002 and INTerpath-009 of Adjuvant Intismeran Autogene Plus Pembrolizumab for Non-Small Cell Lung Cancer

  Annals of Thoracic Surgery Short Reports · 2026-04-01

• Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy

  Radiotherapy and Oncology · 2026-03-31

• 238P Neoadjuvant divarasib shows manageable safety and promising activity in patients with resectable, early-stage, KRAS G12C+ NSCLC: First results from the NAUTIKA1 KRAS G12C+ cohort

  ESMO Open · 2026-03-17

• Reply to: “NeoADAURA: Can We Afford to Overlook Objective Response Rates?” and “Is Major Pathologic Response the Best Surrogate End Point for Neoadjuvant Trials?”

  Journal of Clinical Oncology · 2025-12-19

• Risk and Outcomes of Secondary Cancer Among Lung Cancer Survivors After Definitive Treatment

  JAMA Network Open · 2025-12-09 · 1 citations

• Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry

  JCO Precision Oncology · 2025-12-01

• Supplementary Figure S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

  2025-11-25

• Supplementary Figure S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

  2025-11-25

• Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

  2025-11-25

• Supplementary Figure S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

  2025-11-25